- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01133522
Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 145 in Subjects With Hyperlipidemia on Stable Doses of a Statin
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants receiving low-to-moderate-dose statins were randomized in a 1:3 ratio to receive subcutaneous placebo or evolocumab and enrolled sequentially into one of 5 dose-escalation cohorts:
- Evolocumab 14 mg/placebo once weekly (QW) × 6 doses
- Evolocumab 35 mg/placebo once weekly (QW) × 6 doses
- Evolocumab 140 mg/placebo every 2 weeks (Q2W) × 3 doses
- Evolocumab 280 mg/placebo every 2 weeks (Q2W) × 3 doses
- Evolocumab 420 mg/placebo every 4 weeks (Q2W) × 2 doses.
Participants receiving high-dose statins were randomized 1:3 to receive subcutaneous placebo or evolocumab 140 mg every 2 weeks × 3 doses (Cohort 6).
Participants diagnosed with familial hypercholesterolemia (HeFH) were randomized 1:2 to receive subcutaneous placebo or evolocumab 140 mg every 2 weeks × 3 doses (Cohort 7).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women ages 18 to 70 years (inclusive) at the time of screening with hyperlipidemia
- Body mass index (BMI) ≥18 and ≤ 35 kg/m^2 at the time of screening
- Low-density lipoprotein cholesterol (LDL-C) level of 70-220 mg/dL (inclusive) at screening as measured by direct assay
- For Cohorts 1-5: On a stable dose of rosuvastatin (Crestor) < 40 mg/day, atorvastatin (Lipitor) < 80 mg/day, or simvastatin (Zocor) 20-80 mg/day for ≥ 1 month prior to enrollment and expected to remain on this dose for the remainder of the study
- For Cohort 6: On a stable dose of rosuvastatin (Crestor) 40 mg/day or atorvastatin (Lipitor) 80 mg/day for ≥ 1 month prior to enrollment and expected to remain on this dose for the remainder of the study
- For Cohort 7: Diagnosis of heterozygous familial hypercholesterolemia, based on a score of ≥ 9 points using the World health Organization (WHO) criteria
Exclusion Criteria:
- Diagnosis of homozygous familial hypercholesterolemia
- History of heart failure, coronary artery bypass graft, or cardiac arrhythmia
- History of acute coronary syndrome (e.g. myocardial infarction, hospitalization for unstable angina) or percutaneous coronary intervention, within 12 months prior to enrollment
- Planned cardiac surgery or revascularization
- Known aortic, peripheral vascular or cerebrovascular disease (including history of stroke or transient ischemic attack)
Diabetes mellitus with any of the following:
- known microvascular or macrovascular disease
- HbA1c > 8.0% at screening
- use of any hypoglycemic medication other than metformin
- Uncontrolled hypertension (systolic blood pressure ≥ 150 or diastolic blood pressure ≥ 90 mmHg) either on or off therapy at screening or at baseline
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Evolocumab
Participants received one of 5 dose levels of evolocumab administered as multiple subcutaneous doses.
|
Administered by subcutaneous injection
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Participants received matching placebo dose regimens by subcutaneous injection.
|
Administered by subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events
Time Frame: From the first dose of study drug until Day 85
|
The relationship of each adverse event to the investigational product was assessed by the investigator. A serious adverse event (SAE) is defined as an adverse event that
|
From the first dose of study drug until Day 85
|
Number of Participants With Anti-Evolocumab Antibodies
Time Frame: From the first dose of study drug until Day 85
|
Serum samples were analyzed by an electrochemiluminescence (ECL)-based immunoassay for anti-evolocumab binding antibodies.
Positive samples were subsequently tested in a receptor-ligand binding bioassay for anti-evolocumab neutralizing antibodies
|
From the first dose of study drug until Day 85
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax) of Evolocumab
Time Frame: Day 1, predose and Days 4, 8, 15, 22, 29, 36, 40, 43, 50, 57, 64, 71, 78, and 85
|
Serum concentrations of evolocumab were measured by a validated enzyme-linked immunosorbent assay (ELISA).
The lower limit of quantification (LLOQ) was 800 ng/mL.
|
Day 1, predose and Days 4, 8, 15, 22, 29, 36, 40, 43, 50, 57, 64, 71, 78, and 85
|
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Evolocumab
Time Frame: Day 29 predose (last dose for Cohorts 3-7) and Days 36 (predose for Cohorts 1 and 2), 40, 43, 50, 57, 64, 71, 78, and 85
|
Area under the unbound evolocumab serum concentration-time curve from time of last dose to time of last quantifiable concentration following the last dose of evolocumab.
|
Day 29 predose (last dose for Cohorts 3-7) and Days 36 (predose for Cohorts 1 and 2), 40, 43, 50, 57, 64, 71, 78, and 85
|
Percent Change From Baseline to End of the Dosing Interval in LDL-C
Time Frame: Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group
|
Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group
|
|
Percent Change From Baseline to End of the Dosing Interval in PCSK9
Time Frame: Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group
|
Serum PCSK9 concentrations were determined by using a qualified enzyme-linked immunosorbent assay (ELISA).
The lower limit of quantification (LLOQ) was 15 ng/mL.
|
Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20080398
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipidemia
-
Drug Commission of the German Medical AssociationMadaus AGTerminatedHypercholesterolemia | Combined Hyperlipidemia
-
Misr University for Science and TechnologyActive, not recruiting
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesterolemia and HyperlipidemiaChina
-
Jeil Pharmaceutical Co., Ltd.CompletedHypertension With HyperlipidemiaKorea, Republic of
-
PfizerWithdrawnPrimary Hyperlipidemia or Mixed DyslipidemiaChina
-
ShionogiIntegriumCompletedCombined HyperlipidemiaUnited States
-
IlDong Pharmaceutical Co LtdCompletedHypertension With HyperlipidemiaKorea, Republic of
-
HK inno.N CorporationCompletedHypertension With Hyperlipidemia
-
LG Life SciencesCompletedHypertension, HyperlipidemiaKorea, Republic of
Clinical Trials on Evolocumab
-
Hospital General Universitario Gregorio MarañonCompleted
-
First Affiliated Hospital of Fujian Medical UniversityRecruiting
-
AmgenCompletedMixed Dyslipidemia | Primary HypercholesterolemiaUnited States, Canada
-
Rigshospitalet, DenmarkWithdrawnLipid Lowering, Vascular InflammationDenmark
-
AmgenOrganization of Teratology Information Specialists (OTIS) Research Center...TerminatedHypercholesterolemia; ASCVD; Pregnancy
-
AmgenCompletedMixed Dyslipidemia | Primary HypercholesterolemiaUnited States, Canada
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompleted
-
AmgenTerminatedMixed Dyslipidemia | Primary HypercholesterolemiaChina
-
AmgenCompletedHomozygous Familial Hypercholesterolemia HoFHIndia
-
LIB Therapeutics LLCCompletedHomozygous Familial HypercholesterolemiaUnited States, Israel, Norway, South Africa, Turkey, India